Product Availability Key

  • Mexico and Canada flagMexico and Canada
  •  Outside North America flag Outside North America
  •  US flag US
  • Mexico and Canada flag
  •  Outside North America flag
  •  US flag

CAT #: 14120019

FLT3 ITD MRD Assay

Assay Use

This Research Use Only assay targets the juxtamembrane (JM) region of the FLT3 gene to identify ITD mutations using the Illumina® MiSeqTM platform.

Product Details

  • Summary and Explanation of the Test

    BACKGROUND

    Mutations in the fms-like tyrosine kinase 3 (FLT3) gene are the most prevalent mutations found in acute myeloid leukemia (AML) and are characterized by an aggressive phenotype with a high prevalence of relapse.1  Internal tandem duplications (ITD) within the juxtamembrane domain are the most common mutations of the FLT3 gene and occur in about 25% of newly diagnosed AML patients.2,3 The development of a sensitive and specific assay to estimate the variant read frequency (VRF) of FLT3 ITD MRD represents a significant advancement for AML research. 

     

    PRODUCT SUMMARY

    Invivoscribe’s FLT3 ITD MRD Assay is an NGS-based, targeted, deep-sequencing assay that detects and monitors DNA sequences specific to identified mutations from the primary sample identified at diagnosis at an allelic sensitivity level of 5×10-5. This assay enables clinicians to identify subjects with no overt evidence of disease that may benefit from continuation or modification of treatment.4

    MRD detection by Next-Generation Sequencing has demonstrated utility in predicting clinical outcomes and in generating clinically actionable results, allowing early intervention, confirmation of disease status prior to transplant, and increased confidence in remission status.

  • Principles of the Procedure

    Polymerase chain reaction (PCR) amplification for the detection of the FLT3 ITD mutation is used on DNA isolated from the sample. Barcoded primers amplify the sequences of interest. The ITD wild type produces a fragment that is 327 bp, while the presence of an insertion produces a fragment that is ≥ 330 bp. This assay has an analytical sensitivity of 5 x 10-5 mutant alleles per total alleles. Note, this analytical sensitivity was validated for an ITD size of 30 bp. While the maximum ITD size detectable by this assay is 252 bp, the detectable size and sensitivity vary depending on an ITD’s insertion location and sequence.

  • Specimen Requirements

    This RUO assay tests genomic DNA isolated from peripheral blood or bone marrow. The minimum input quantity is 700 ng of high quality DNA.

References

1. The Cancer Genome Atlas Research Network. (2013) New England Journal of Medicine. 368: 2059–2074.
2. Konig, H et al. (2015) Expert Opinions in Therapeutic Targets. 19:37-54.
3. Daver N et al. Leukemia. (2019) 33:299-312.
4. Levis, MJ et al. (2018) Blood Advances. 2: 825-831.

Disclaimer

This product is for Research Use Only; not for use in diagnostic procedures.

Legal Notice

Now Available

Our New Document Search Feature
SEARCH ⟶

Need Help Placing an Online Order?

Contact our Customer Service Team
CONTACT CUSTOMER SERVICE ⟶

Now Available

Our New Document Search Feature
SEARCH ⟶

Need Help Placing an Online Order?

Contact our Customer Service Team
CONTACT CUSTOMER SERVICE ⟶
LATEST NEWS
Invivoscribe Announces Key Submission in the EU ⟶

CONNECT